

Contact:

Loraine V. Upham

Lori@CureDM.com

(505-515-1947)

CureDM Collaborates with University of New Mexico in Pancreatic Progenitor Cell Study

Wilmington, DE – February 7, 2014 – CureDM announces that data from the collaboration with University of New Mexico Dream Lab, “Effects of HIP2B on Fetal Pancreatic Progenitor Cells”, was accepted for presentation at the 2014 Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting in Vancouver, BC, Canada and the 2014 Eastern SPR Annual Meeting, March 21-23, in Philadelphia, PA.

“We are very pleased to be collaborating with the University of New Mexico Lab led by Dr. Robin Ohls and her team. They have access to cells and ability to culture pancreatic progenitor cells for study of effects of our drug on the important transcription factors that are triggered in the process of islet neogenesis,” explains founder, Loraine Upham. The CureDM drug, HIP2B is a human derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets. Both type 1 and type 2 indications will be pursued.

About CureDM

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit www.curedm.com.

XXXXXX